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Abstract It has been persuasively shown in the last two
decades that the development of heart failure is closely
linked to distinct alterations in Ca2? cycling. A crucial
point in this respect is an increased spontaneous release of
Ca2? out of the sarcoplasmic reticulum during diastole via
ryanodine receptors type 2 (RyR2). The consequence is a
compromised sarcoplasmic reticulum Ca2? storage capac-
ity, which impairs systolic contractility and possibly dia-
stolic cardiac function due to Ca2? overload. Additionally,
leaky RyR2 are more and more regarded to potently induce
proarrhythmic triggers. Elimination of spontaneously
released Ca2? via RyR2 in diastole can cause a transient
sarcolemmal inward current and hence delayed after
depolarisations as substrate for cardiac arrhythmias. In this
article, the pathological role and consequences of the SR
Ca2?-leak and its regulation are reviewed with a main
focus on protein kinase A and Ca2?-calmodulin-dependent
kinase II. We summarise clinical consequences of ‘‘leaky
RyR2’’ as well as possible therapeutic strategies in order to
correct RyR2 dysfunction and discuss the significance of
the available data.
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Prevalence and socioeconomic relevance
of heart failure
Heart failure is characterised by a progressive deterioration
of cardiac function and represents a major public health
burden. Despite a number of well-established therapies, the
prevalence as well as the mortality of heart failure are still
alarmingly high. Heart failure remains the most frequent
reason for hospital admission of patients older than
65 years [1]. In the USA, the number of hospitalisations
due to heart failure has more than tripled between 1979 and
2004 [2]. The over-all prevalence of heart failure is esti-
mated to be about 2 % [3]. More than 10 % of people older
than 80 years are affected, many of them are highly limited
as to their physical capacities and thus do suffer signifi-
cantly in everyday life. Furthermore, the prognosis of heart
failure patients is still miserable. There are estimated sur-
vival rates of only 50 % 5 years and 10 % 10 years after
diagnosis [4–6].
Aetiology and manifestations of heart failure
Huge efforts have been made to further elucidate under-
lying pathomechanisms and identify new targets for inno-
vative therapies. The aetiologies of heart failure are
various, stretching from coronary artery disease and heart
valve dysfunctions to toxic influences on the myocardium
or infectious diseases. Arterial hypertension could be
identified as the most frequent risk factor in this context
[7]. The common final path is an impairment of myocardial
function. Importantly, systolic as well as diastolic function
can be compromised independently leading to similar
clinical manifestations. Current definitions of heart failure
have taken this into account by distinguishing between
T. H. Fischer  L. S. Maier  S. Sossalla (&)
Department of Cardiology and Pneumology, Heart Center,




Heart Fail Rev (2013) 18:475–483
DOI 10.1007/s10741-012-9339-6
heart failure with preserved ejection fraction (HFpEF) and
heart failure with reduced ejection fraction (HFrEF).
According to the guidelines of the American Heart Asso-
ciation, HFpEF is defined by symptomatic heart failure and
a left ventricular ejection fraction of at least 50 % [8]. This
entity has gained increasing attention in recent years as up
to 50 % of heart failure patients can indeed be classified
there [1, 9] and evidence-based medical therapy is still
lacking.
On a histological and cellular level, heart failure could
be linked to several alterations including fibrosis, inflam-
mation and apoptosis. Furthermore, it has become more
and more obvious that a fully functional excitation–
contraction coupling process in the cardiomyocyte is fun-
damental for both, a normal systolic and diastolic function.
Excitation–contraction coupling and its regulation
Physiological excitation–contraction coupling is the basis
of a sound periodic succession of contraction and relaxa-
tion. It is characterised by a well-defined, triggered Ca2?
release out of the sarcoplasmic reticulum (SR) in systole
followed by a quick Ca2? elimination out of the cytosol to
induce relaxation in diastole (Fig. 1).
During phase 0 of an action potential fast Na?-influx
leads to a steep increase of the membrane potential
increasing the probability that the voltage dependent
L-type Ca2? channels will open. Thereupon Ca2?-ions
passively drawn by a concentration and electrochemical
gradient enter the cytoplasm and maintain the plateau
phase of the action potential. Inside the cell, they bind to
ryanodine receptors type 2 (RyR2) that are located on the
surface of the SR and trigger the release of an even bigger
amount of Ca2? out of the SR. This mechanism of Ca2?-
induced Ca2? release leads to a prominent increase in
cytosolic Ca2? that binds to troponin C (TnC) and thereby
induces actin–myosin interaction. In diastole, Ca2? has to
be eliminated from the cytosol to allow relaxation of the
myofilaments. This is mainly achieved by an active,
energy-consuming Ca2?-reuptake into the SR via the sar-
coplasmic reticulum Ca2?-ATPase type 2a (SERCA2a). A
smaller amount of Ca2? is extruded out of the cell via the
Na?/Ca2?-exchanger (NCX), which is a facilitated diffu-
sion in which the electrochemical potential gradients of
Na? and Ca2? are the source of energy to drive the
transport. NCX in its ‘‘forward’’ mode produces an elec-
trical current because 3 Na? are exchanged for 1 Ca2?. In
human cardiomyocytes, the reuptake of Ca2? into the SR
makes up for approximately 70 % of the systolic Ca2?
depending on the heart rate [10]. Around 28 % are pumped
out of the cell via NCX. The remaining 2 % are allotted to
Ca2? uptake into mitochondria and elimination via Ca2?-
ATPases in the plasma membrane [11].
As the cyclic alterations of cytosolic Ca2? concentra-
tions make up the molecular trigger for cardiac contraction
and relaxation, it is a matter of course that this system is
elaborately regulated and highly adaptable to physical
demands. SERCA2a activity is influenced by phospho-
lamban (PLB) that is one of the major mediators of the
cardiac contractility response upon b-adrenergic stimula-
tion [12]. Inhibition of SERCA2a by PLB is dependent on
the phosphorylation status of PLB and is most pronounced
when PLB is unphosphorylated. Protein kinase A (PKA) as
Fig. 1 Mechanisms of
excitation–contraction coupling
in cardiomyocytes; arrows
indicate Ca2? shifts in systole
(left) and diastole (right); L-type
L-type Ca2? channel; RyR2
ryanodine receptor type 2; SR
sarcoplasmic reticulum; PLB
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well as the Ca2?/calmodulin-dependent protein kinase IId
(CaMKIId) is able to phosphorylate PLB at specific resi-
dues (serine 16 and threonine 17, respectively) and thereby
abandon its inhibitory effect on SERCA2a. A second
subcellular microdomain is the RyR2-complex that con-
sists of several proteins and whose Ca2? release capacity
and diastolic closure can be regulated via phosphorylation
by PKA and CaMKII [13–19] at Ser2809 and Ser2815,
respectively. Furthermore, protein phosphatases 1 and 2a
were found to regulate the phosphorylation status of sev-
eral Ca2? handling proteins [20].
Consequences of altered excitation–contraction
coupling in heart failure: the diastolic leak
Several animal models as well as functional analyses of
human tissue samples have persuasively shown that Ca2?
cycling is profoundly disturbed in heart failure (Fig. 2).
The most distinctive aspect is a reduction of systolic Ca2?
transient amplitude, which is commonly accompanied by
an increase of diastolic Ca2? levels in the cytosol. Fur-
thermore, the velocity of diastolic Ca2? elimination is
reduced [21], and the physiologically positive force-
frequency relation is typically blunted and rather negative-
shaped [10, 22]. These alterations resulting from the Ca2?
depletion of the SR in heart failure can be attributed to two
distinct pathomechanisms with synergistic effects on SR
Ca2? load. On the one hand, the diastolic refill of the SR is
compromised due to a decreased expression and activity of
SERCA2a [10, 23, 24] and a reduction of PLB phos-
phorylation [25]. The regulation of the PLB-SERCA2a-
interaction and the resulting new therapeutic options for the
treatment of heart failure have recently been comprehen-
sively reviewed [26].
On the other hand, there is an increased diastolic Ca2?
loss out of the SR via substantially altered RyR2. It has been
widely shown in different animal models as well as in
human tissue that Ca2? can leave the SR during diastole via
numerous short and tightly localised Ca2? release events, the
so-called Ca2? sparks. A Ca2? spark is generated from a
limited number of clustered RyR2s that form a Ca2? release
unit. The spontaneous opening of one receptor can consec-
utively trigger the activation of neighbouring RyR2s of the
same Ca2? release unit via Ca2?-induced Ca2? release
(CICR) in the dyadic cleft. This locally restricted Ca2?
release is accompanied by a local decrease of SR Ca2?
content in the corresponding areas, the so-called Ca2? blinks
[27], and was shown to terminate when the local SR Ca2?
content reaches a threshold of approximately 60 % of the
diastolic SR Ca2? concentration [28]. The stability of RyR2-
closure is severely compromised in heart failure leading to
an increased diastolic open probability and thus an increased
diastolic leak. Furthermore, the Ca2? ions, once released, are
partly removed from the cytosol via the NCX, which was
found to be overexpressed in heart failure [10, 24, 29].
Fig. 2 Deteriorations of
excitation–contraction coupling
in heart failure; arrows indicate
Ca2? shifts in systole (left) and
diastole (right); diastolic Ca2?
leak is highlighted in red;
changes in protein function and
ion concentrations are indicated
by vertical red arrows; :
increase; ; decrease; L-type
L-type Ca2? channel; RyR2
ryanodine receptor type 2; SR
sarcoplasmic reticulum; PLB
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Extruding two positive electric charges (1 Ca2? ion) in
exchange for three (3 Na? ions) leads to a depolarisation of
the cell membrane and can trigger delayed after depolari-
sations [30]. Thus, as simple as the physiological task of the
RyR2 complex to open quickly and widely in systole and to
close tightly and densely in diastole might appear as far-
reaching are the cellular consequences once it is disturbed. A
leaky RyR2 could possibly be linked to all major drawbacks
of heart failure: impaired systolic force generation, com-
promised passive diastolic relaxation and a disposition for
arrhythmias. Therefore, huge efforts have been made in the
last two decades to further elucidate mechanisms of RyR2
regulation in different physiological states as well as in
different cardiac pathologies [13–15, 17, 18, 27, 31–37].
The ryanodine receptor type 2: the gatekeeper of Ca21
storage
Ryanodine receptors are the largest known ion channels. In the
heart, ryanodine receptor type 2 is the predominantly expres-
sed isoform. It is a huge macromolecular protein exceeding a
molecular weight of 2 MDa. Structural analysis have shown
that RyRs are mushroom-shaped assemblies of four identical
subunits each comprising approximately 5,000 amino acids
[38]. This core part of the RyR2-complex then serves as a
molecular scaffold for further proteins that attach to the
receptor and regulate its function. Calsequestrin, junctin, tria-
din and FK506-binding protein, 12.6 kDa, (FKBP12.6) were
shown to associate with the RyR2 complex [39–42] (Fig. 3).
Calsequestrin is linked to the RyR2 complex via junctin and
triadin [43] and acts as a Ca2? buffer thus influencing RyR2
behaviour. Furthermore, RyR2 function is crucially linked to
its phosphorylation status, which can be seen as the net effect
of a steady competition between two major cellular kinases,
PKA and CaMKII, and two protein phosphatases, PP1 and
PP2a, all of which are closely associated with the receptor [44].
This close proximity enables dynamic changes of the phos-
phorylation status upon subcellular signals [44]. The relative
phosphorylation of the receptor complex influences its Ca2?
sensitivity and thus the diastolic open probability as well as the
systolic Ca2? release capacity [14, 45] by inducing confor-
mational changes of the RyR2 complex. The RyR2 complex
therefore acts as a molecular switchboard, transducing cellular
signals to the Ca2? release pore and thus adapting Ca2? release
kinetics to cellular demands.
Mechanisms of RyR2 dysregulation in heart failure
The mechanisms of RyR2 regulation have been subject of
intense research in the last years due to their pathologic
relevance. It has become undoubtedly clear that phosphor-
ylation of the receptor protein is a key event in this context.
The RyR2 complex thereby was found to be one of the first
proteins that undergo phosphorylation upon beta-adrenergic
stimulation [19]. As early as in 1991, it was described that
RyR2 can be phosphorylated by CaMKII in canine cardio-
myocytes, which leads to an activation of this Ca2?-release
channel [19]. Furthermore, it could be demonstrated shortly
Fig. 3 Development of an increased diastolic Ca2? leak in heart
failure; normal diastolic ryanodine receptor 2 (RyR2) closure (left) vs.
diastolic SR Ca2? leak due to spontaneous opening of a hyperphos-
phorylated RyR2 complex (right); the four subunits of the RyR2
complex are illustrated in grey and black; the diastolic leak is
highlighted in red; relevant phosphorylation sites at the RyR2-protein
are indicated; changes in protein function are indicated by vertical red
arrows; : increase; ; decrease; SR sarcoplasmic reticulum; PP1
protein phosphatase 1; PP2A protein phosphatase 2A; CaMKIId Ca2?
calmodulin depending kinase IId; PKA protein kinase A; P phosphate
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after by a different group that the phosphorylation of RyR2
receptors in rat cardiomyocytes upon beta-adrenergic
stimulation was PKA dependent [46]. From that time on,
both kinases were intensively studied as to their impact on
the RyR2 in different animal models as well as human heart
tissue—with controversial results up to date.
The role of PKA in the development of an increased
SR Ca21-leak
It was described by Marks and colleagues that PKA phos-
phorylation of the RyR2 leads to a dissociation of FKBP12.6
from the channel and consecutively to an increased Ca2?
sensitivity and compromised diastolic RyR2 closure [14].
Some years later, the same group proposed Ser2808 as the
only functional PKA phosphorylation site on the RyR2 by
showing that immunoprecipitated RyR2 from S2808A
mutant mice could not be phosphorylated by PKA [16]. In
contrast to their wild-type littermates these S2808A mutant
mice did not show any PKA phosphorylation of RyR2 after
isoproterenol treatment in vivo. Furthermore, these mice
exhibited significantly improved cardiac function compared
to wild type after myocardial infarction and were thus pro-
tected from maladaptive remodelling. Marks and colleagues
also found a hyperphosphorylation of RyR2 at S2809 in
overt human heart failure [16]. On account of these findings,
a hyperphosphorylation of RyR2 by PKA had been proposed
as central mechanism in the pathogenesis of heart failure.
The scenario of persistent PKA activation in heart failure
due to chronic activation of the sympathetic nervous system
also fits to clinical observations, as most heart failure
patients do have elevated catecholamine levels. Beta-
adrenergic receptors have been reported to be downregu-
lated [47]. Other groups, however, contradicted the data on
the functional relevance of PKA-dependent RyR2 hyper-
phosphorylation. It could be shown in mouse ventricular
myocytes that PKA phosphorylation of the RyR2 did not
significantly affect diastolic SR Ca2? leak [48]. Further-
more, another group rather found an intact beta-adrenergic
response and an unmodified progression towards heart
failure in mice with the same genetic ablation of the major
PKA phosphorylation site (S2808A) [49]. In this study, the
authors only found slight modifications of single-channel
activity in Ser2808-mutated mice that allowed for normal
Ca2? transients and unaltered overall cellular function.
Obvious protection against maladaptive remodelling after
TAC was absent. Moreover, they did not find a significant
impact of RyR-S2808A mutation on the diastolic SR Ca2?
leak and showed that RyR2-S2808A mutants could still be
phosphorylated by PKA, which might be attributed
to another phosphorylation site at S2830. The authors fur-
ther concluded that genetic ablation of one single
phosphorylation site might lead to conformational changes
and shift kinase activity to other, physiologically not equally
relevant sites that in turn make up for the missing phos-
phorylation site. Furthermore, different amounts of phos-
phatases included in the isolated RyR2 complexes could, at
least partially, explain the contradictory results of different
works in the field. Another group just recently exposed RyR-
S2808A-mutated mice to myocardial infarction. They,
however, could not find any differences compared with
wild-type littermates, neither as to global cardiac function
and calcium cycling parameters after myocardial infarction
nor as to infarct size [50].
FKBP12.6: a key player of RyR stabilisation
or just a side show
Several studies strongly support the hypothesis that phos-
phorylation of RyR2 at Ser2808 by PKA causes the RyR2-
associated protein FKBP12.6 to dissociate from the receptor
with the result of an increased propensity for diastolic SR
Ca2? release [14, 51, 52]. However, these observations were
challenged by several groups. Xiao et al. [53] examined the
binding behaviour of FKBP12.6 with unphosphorylated and
phosphorylated RyR2 proteins and did not find significant
differences. Complete phosphorylation of Ser2808 by
exogenous PKA did not disrupt FKBP12.6-RyR2 com-
plexes and a S2808D mutated receptor that corresponds to a
constitutively phosphorylated state of Ser2808 and thus
mimics a constitutive phosphorylation also retained the
ability to bind FKBP12.6 [53]. Another group examined the
effect of a sticky FKBP12.6 mutant on the development of
heart failure [54]. They generated mice expressing a
FKBP12.6 (D37S) mutant that binds with greater stability to
the RyR2. These mice showed increased SR Ca2? load but
did not exhibit any attenuation of cardiac functional decline
after aortic banding. Another aspect that argues against an
important, physiologically relevant FKBP12.6-mediated
RyR2 regulation is the small amount of FKBP12.6 normally
existing in rat and mouse myocytes [55]. FKBP12.6 was
found to be numerically far less abundant in these cells than
RyR2-receptors. This in turn means that the bulk of RyR2
proteins physiologically already lacks FKBP12.6 and might
explain why some groups did not see any obvious effect of
physiologically expressed FKBP12.6 on RyR2 gating while
studies using animals overexpressing FKBP12.6 showed
relevant effects an SR Ca2? leak and SR Ca2? content
[56, 57].
Whereas the activating effect of PKA on L-type Ca2?
channels [58] and SERCA2a via PLB phosphorylation [59]
is indisputable, its direct impact on RyR2 function and the
role of FKBP12.6 dissociation is still not finally elucidated.
The discrepancies of different studies in this field are
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difficult to explain. The varying outcomes in different
mouse models harbouring the same RyRS2808A mutation
might, at least partially, be attributed to different genetic
backgrounds of the mouse lines used. Furthermore, the
potency of cardiomyocytes to compensate artificially intro-
duced defects of Ca2? cycling cannot be overestimated. It
has been shown that mice with a conditional knockout of
the NCX could escape death by an adaptive reduction
of Ca2? influx through L-type Ca2? channels instead of
upregulation of Ca2? efflux mechanisms [60]. This, how-
ever, means in turn that the validity of data from geneti-
cally altered animal models and their applicability for the
explanation of pathomechanisms in human disease have to
be handled with care. Eventually, functional data in human
tissue will be needed to resolve this issue.
The role of CaMKII for the development
of an increased SR Ca21 leak
There is an increasing body of knowledge concerning the
crucial role of CaMKII for modulation of RyR2 function.
Different sequence analysis revealed that there are up to
four serine and two threonine residues at the RyR2 that can
be phosphorylated by CaMKII. The first report was pub-
lished by Witcher et al. [19], showing a direct phosphor-
ylation of the myocardial RyR2 at Ser2809 by CaMKII.
However, site-directed mutagenesis experiments showed
that CaMKII binding at RyR2 might not be at Ser2809,
which is supposed to be the PKA-dependent phosphoryla-
tion site, but at Ser2815 [13]. CaMKII-dependent RyR2
phosphorylation thereby resulted in a more pronounced
RyR2 activation than PKA-dependent RyR2 phosphor-
ylation. Additionally, this group clearly showed that
CaMKII-dependent RyR2 phosphorylation increased the
open probability of the cardiac RyR2 in lipid bilayer
experiments. Some years later, it was also shown by Huke
et al. [36] that the phosphorylation of RyR2 at Ser2814 by
CaMKII rather than PKA-dependent phosphorylation at
Ser2808 is crucial for RyR2 function. However, there are
also reports that suggested a reduced SR Ca2? leak due to
CaMKII phosphorylation of the cardiac RyR2 [61].
After the discovery of RyR2 phosphorylation by
CaMKII, several other groups confirmed the pathologically
relevant impact of CaMKII on RyR2 function in animal
models as well as in human disease [15, 17, 18, 31, 34, 62].
A transgenic mouse line overexpressing the CaMKIIdc
exhibited severe alterations of Ca2? cycling and dilated
heart failure [15, 34]. An increased diastolic Ca2? leak in
these mice lead to a severe depletion of SR Ca2? storage
and reduced systolic Ca2? transients [15, 34].
Furthermore, Ai et al. [32] could show in 2005 that the
enhanced SR Ca2? leak in isolated cardiomyocytes from a
rabbit heart failure model could be reduced by CaMKII
inhibition but not by PKA inhibition. Curran et al. [63]
proposed that even the inotropic response upon beta-
adrenergic receptor stimulation is caused by CaMKII. The
fact that CaMKII was shown to be activated by auto-
phosphorylation as well as oxidation [64, 65] enables a
vicious circle to set in during conditions of diastolic Ca2?
overload and shortage of energy supply in heart failure
leading to chronic CaMKII activation. These findings could
recently be confirmed for human heart failure by our group
[17]. CaMKII expression and phosphorylation were shown
to be increased in left and right ventricular tissue probes of
human heart failure. Inhibition of CaMKII yielded a
reduction of SR Ca2? leak in human cardiomyocytes iso-
lated from failing hearts and improved SR Ca2? storage.
Furthermore, positive inotropic effects could be detected in
twitching muscle preparations after CaMKII inhibition
during increasing stimulation frequencies. These data
provide compelling evidence for an important pathological
role of CaMKII in heart failure.
There is also increasing evidence for the role of the
CaMKII-induced diastolic Ca2? leak in the development of
arrhythmias. Isolated cardiomyocytes from mice over-
expressing CaMKIIdc [15] showed an increased incidence
of early after-depolarisations compared with wild type
leading to an increased number of potentially arrhythmic
spontaneous action potentials [18]. These proarrhythmic
events could be further increased by isoproterenol treat-
ment and were significantly reduced by CaMKII inhibition
[18]. A recent study could link the increased incidence of
arrhythmias in ischaemic canine heart tissue to a CaMKII-
related shortening of the Ca2? signalling refractoriness
[66]. It could further be shown that the progression of
human heart failure is associated with a continuous
increase in RyR2-mediated Ca2? leak, which is paralleled
by an increased incidence of diastolic spontaneous Ca2?
waves [33]. The aetiology underlying the development of
heart failure might also play an important role regarding
the cellular pathomechanisms involved. A recent study
showed that RyR2 is only hyperphosphorylated at the
CaMKII-dependent site Ser2815 in non-ischaemic, but not
in ischaemic heart failure [67]. Accordingly, mice har-
bouring a mutation at Ser2814 (S2814A) were protected
from afterload-induced heart failure after trans-aortic
constriction but not from ischaemic heart failure after
myocardial infarction. More studies will be needed to
resolve this issue. Other studies directly linked the SR
Ca2? leak and an increased CaMKII activity to atrial
fibrillation (AF), the most common sustained cardiac
arrhythmia [68, 69]. It could be shown that CaMKII
expression and its phosphorylation are significantly
increased in right atria of AF patients compared with
patients in stable sinus rhythm, which was accompanied by
480 Heart Fail Rev (2013) 18:475–483
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an increased RyR2 phosphorylation at the CaMKII-specific
site Ser2814 [68, 69]. Diastolic Ca2? levels were found to
be increased as the result of an increased diastolic Ca2?
leak. Both findings could be normalised by CaMKII inhi-
bition [68]. These data could be nicely confirmed by a
recent study [70], which also showed that the SR Ca2? leak
could be reduced in AF cells by CaMKII inhibition
whereas PKA inhibition did not yield relevant effects on
the SR Ca2? leak again stressing the role of CaMKII under
pathophysiological conditions as compared to PKA.
RyR2 stabilisers and CaMKII inhibitors
The use of CaMKII inhibitors in patients is significantly
hindered by the ubiquitous expression of this enzyme in
different organs. Currently available CaMKII inhibitors
cannot be administered to patients due to unspecific effects
and pharmacodynamic problems (e.g. oral application of
peptide inhibitors). Major hurdles as to organ-specific
attribution still have to be overcome. Gene therapy-based
approaches might, however, be feasible in the near future.
Additionally, several compounds directly leading to a sta-
bilisation of diastolic RyR2 closure have already been
developed. The major challenge thereby is to identify
compounds that exert a beneficial effect on the diastolic
leak without compromising systolic RyR2 opening and
Ca2? release. One of the first compounds that combined
both features was JTV519. It was shown to improve dia-
stolic and systolic function in isolated human failing
myocardium but also had unspecific effects on other ion
channels and a narrow therapeutic range with negative
inotropic effects at higher concentrations [71–73]. A newer
and more specific drug called S44121 has been developed
and is currently being evaluated in a phase 2 multicentre
clinical study (ISRCTN reg. number 14227980).
Conclusion
Taken together, the RyR2-dependent SR Ca2? leak has
emerged as a pivot in the development of cardiac
arrhythmias as well as heart failure under various condi-
tions and therefore represents a promising toehold for
future therapies. Whereas the direct contribution of PKA
to the development of an increased SR Ca2? leak is still
controversial, the crucial role of CaMKII in this context
seems to be more established. There are convincing data
from animal models as well as human tissue showing that
an increased CaMKII activity in cardiac pathologies
contributes to the manifestation of pump failure and
arrhythmias and that CaMKII inhibition can yield bene-
ficial effects. Thus, to our current knowledge, the diastolic
SR Ca2? leak can be addressed by two different approa-
ches: direct stabilisation of the leaky RyR2 via suitable
new compounds (RyR stabilisers) on the one hand and
reduction of its hyperphosphorylation by CaMKII inhi-
bition on the other hand. The clinical implications for
both approaches would be various, stretching from
arrhythmias to systolic pump failure as well as diastolic
dysfunction.
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